Inclusion Criteria:

- Histologically documented, inoperable, unresectable, incurable, locally advanced,
recurrent or metastatic (Stage IIIB or Stage IV) non-small cell lung cancer. (Note:
Histology is the preferred method of diagnosis. However, in case only cytology is
available, specimens from brushing, washing or needle aspiration etc. are acceptable
for diagnosis. Sputum cytology alone is not acceptable)

- No prior chemotherapy or therapy with systemic anti-tumour therapy (e.g., monoclonal
antibody therapy). Prior surgery and/or localized irradiation (palliative RT or
curative RT) is permitted. Pre operative or post operative anti neo-plastic therapy
is allowed if ended more than 2 years ago

- No prior exposure to agents directed at the HER axis (e.g. EGFR TK Inhibitors,
Herceptin)

- Measurable disease as defined by RECIST criteria (attachment 1)

- Age 18 or greater

- ECOG performance status of 0 - 2 (attachment 2)

- Life expectancy of at least 12 weeks

- At least 4 weeks since any prior surgery or radiotherapy. Patients who, in the
opinion of the investigator, have fully recovered from surgery in less than 4 weeks
may also be considered for the study. Patients must have recovered (CTC < 1) from
acute toxicities of any previous therapy

- Granulocyte count > 1.5 x 109/L, platelet count > 100 x 109/L and hemoglobin >8.0
g/dL

- Serum bilirubin must be < 1.5 upper limit of normal (ULN) or ≤ 5 times ULN in
patients with liver metastases. SGOT (AST) and SGPT (ALT) must be < 3 x ULN.

- Serum creatinine < 1.5 ULN or creatinine clearance > 60 ml/min

- Normal serum calcium

- Able to comply with study and follow-up procedures

- For all females of childbearing potential a negative pregnancy test must be obtained
within 48 hours before registration starting therapy

- Patients with reproductive potential must use effective contraception

- Written (signed) Informed Consent to participate in the study.

Exclusion Criteria:

- Any unstable systemic disease [including active infection, uncontrolled hypertension,
unstable angina, New York Heart Association (NYHA) Class III or IV heart failure
(Attachment 3, NYHA Classification of Cardiac Disease), myocardial infarction within
the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal or
metabolic disease] or Serious medical or psychiatric illness likely to interfere with
participation in this clinical study

- Any other malignancies within 5 years (except for adequately treated carcinoma in
situ of the cervix or basal or squamous cell skin cancer)

- Patients are excluded if they have brain metastasis or spinal cord compression that
is newly diagnosed and/or has not yet been definitively treated with surgery and/or
radiation; previously diagnosed and treated CNS metastases or spinal cord compression
with evidence of stable disease (clinically stable imaging) for at least 2 months is
permitted

- Any diseases, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of the study drug or that might affect the interpretation of
the results or render the subject at high risk from treatment complications

- Nursing mothers

- Has known or suspected hypersensitivity or intolerance to boron, mannitol, or
heparin, if an indwelling catheter is used

- Neuropathy ³ Grade 2